London
· Delayed Price · Currency is GBP · Price in USD uniQure Company Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease.
In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 1998 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 480 |
| CEO | Matthew Kapusta |
Contact Details
Address: Paasheuvelweg 25 Amsterdam, 1105 BP Netherlands | |
| Phone | 31 20 240 6000 |
| Website | uniqure.com |
Stock Details
| Ticker Symbol | 0EE0 |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | NL0010696654 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Matthew Kapusta | Chief Executive Officer |
| Christian Klemt | Chief Financial Officer |